EndoPredict®

EndoPredict provides accurate results for patients diagnosed with ER+, HER2-, early-stage breast cancer with either node-negative or node-positive disease (1-3 nodes).  The test combines a 12-gene molecular score (tumor biology) with tumor size and nodal status (tumor pathology).  EndoPredict provides an individualized early and late recurrence result for each patient based on their tumor’s biology and pathology. With the integration of these specific features, Endopredict also accurately predicts an individualized absolute chemotherapy benefit to help make the right treatment decision for each individual case of breast cancer.

myChoice® HRD

A comprehensive tumor test that determines HRD status in patients with ovarian cancer.

myRisk® and myRisk® Single Gene Panels

Hereditary Cancer assessments for elevated risk of Breast, Ovarian, Endometrial, Prostate, Melanoma, Pancreatic, Colorectal and Gastric cancers

Prolaris®

Prolaris is a genomic test developed to aid healthcare professionals in predicting prostate cancer aggressiveness in conjunction with clinical parameters such as Gleason score and PSA.

 GeneSight®

GeneSight is a pharmacogenomic test that analyzes how your genes may affect medication outcomes. The GeneSight test analyzes clinically important genetic variations in your DNA. Results can inform your doctor about how you may break down or respond to certain medications commonly prescribed to treat depression, anxiety, ADHD, and other psychiatric conditions.

If you have questions about the test or ordering process, our customer service team is available to assist you by email at noviscend@patientcaresolutions.com or by phone at 1-844-697-4231.